Navigation Links
Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org
Date:8/23/2014

Dallas, Texas (PRWEB) August 23, 2014

Cardiomyopathy (heart muscle disease) is the measurable deterioration of the function of the myocardium (the heart muscle) for any reason, usually leading to heart failure; common symptoms are dyspnea (breathlessness) and peripheral edema (swelling of the legs). People with cardiomyopathy are often at risk of dangerous forms of irregular heart beat and sudden cardiac death. The most common form of cardiomyopathy is dilated cardiomyopathy.

Clinical trial report, “Cardiomyopathy Global Clinical Trials Review, H2, 2014? provides data on the Cardiomyopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Cardiomyopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Cardiomyopathy.

Complete report details at http://www.marketoptimizer.org/cardiomyopathy-global-clinical-trials-review-h2-2014.html .

Scope

  •     Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  •     Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  •     Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  •     Understand the dynamics of a particular indication in a condensed manner
  •     Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  •     Obtain discontinued trial listing for trials across the globe
  •     Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Order a purchase copy at http://www.marketoptimizer.org/contacts/purchase?rname=9647 .
(This is a premium report priced at US$2500 for a single user License and US $7500 for Corporate User License)

Major Table of Contents for This Report

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Cardiomyopathy
Report Guidance

Clinical Trials by Region
Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Countries Contributing to Clinical Trials in Middle East and Africa
Top Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Cardiomyopathy to Cardiovascular Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Cardiomyopathy to Cardiovascular Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase

In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Unaccomplished Trials of Cardiomyopathy
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors

Top Companies Participating in Cardiomyopathy Therapeutics Clinical Trials
Prominent Drugs
Clinical Trial Profiles
Clinical Trial Overview of Top Companies
Johnson & Johnson
Clinical Trial Overview of Johnson & Johnson
Gilead Sciences, Inc.
Clinical Trial Overview of Gilead Sciences, Inc.
Pfizer Inc.
Clinical Trial Overview of Pfizer Inc.
Les Laboratoires Servier SAS
Clinical Trial Overview of Les Laboratoires Servier SAS
Celladon Corporation
Clinical Trial Overview of Celladon Corporation
Aastrom Biosciences, Inc.
Clinical Trial Overview of Aastrom Biosciences, Inc.
Bayer AG
Clinical Trial Overview of Bayer AG
Array BioPharma Inc.
Clinical Trial Overview of Array BioPharma Inc.
AAVLife
Clinical Trial Overview of AAVLife
A. Menarini Industrie Farmaceutiche Riunite Srl
Clinical Trial Overview of A. Menarini Industrie Farmaceutiche Riunite Srl
Clinical Trial Overview of Top Institutes / Government
National Heart, Lung, and Blood Institute
Clinical Trial Overview of National Heart, Lung, and Blood Institute
University of Pittsburgh
Clinical Trial Overview of University of Pittsburgh
Johns Hopkins University
Clinical Trial Overview of Johns Hopkins University
Assistance Publique – Hopitaux de Paris
Clinical Trial Overview of Assistance Publique – Hopitaux de Paris
University of Michigan
Clinical Trial Overview of University of Michigan
Osaka University
Clinical Trial Overview of Osaka University
Maastricht University Medical Center
Clinical Trial Overview of Maastricht University Medical Center
University Health Network
Clinical Trial Overview of University Health Network
Johann Wolfgang Goethe University Hospitals
Clinical Trial Overview of Johann Wolfgang Goethe University Hospitals
Stanford University
Clinical Trial Overview of Stanford University
Five Key Clinical Profiles

Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/energy-power/energy.

About Us:
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/cardiomyopathy-clinical/trials-review-h2-2014/prweb12116856.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Beware: Newly recognized heart cardiomyopathy is not always benign
2. Biomarker test for Peripartum Cardiomyopathy could help reduce death after giving birth
3. Ronald S. Weaver, MD, Owner of Global Cardio Care Centers, Announces EECP Treatment Success for Cardiomyopathy Patient Who Needed Heart Transplant
4. Soy-based S-equol supplement reduces hot flash frequency, muscle & joint pain in US women
5. Accelerated chemotherapy given before surgery benefits patients with muscle-invasive bladder cancer
6. Mayo Clinic study links healthy muscle mass to healthy bones, finds differences by gender
7. Experimental drug improves muscle strength among male cancer patients
8. Muscle Mass Linked to Bone Health in Some Parts of Body
9. Heuer M.D. Research Announces CardiaShred™ - First Medical Doctor Formulated, Heart Healthy Weight Loss, Energy and Lean Muscle Building Supplement
10. Strong communication between brain and muscle requires both having the protein LRP4
11. Lab-engineered muscle implants restore function in animals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center for ... and wellness program, at their world headquarters of Omni La Costa Resort & Spa ... to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and physical ...
(Date:12/8/2016)... ... 2016 , ... STATEN ISLAND, N.Y., Nov. 24, 2016 — ... highest standards of trauma, maternity, cancer and chronic obstructive pulmonary disease (COPD) services ... Daniel Messina. , Among the recognitions, the American College of Surgeons' (ACS) named ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... the Affordable Care Act. Dr. Botelho advocates for the mass media launching of ... gives people ongoing opportunities to share their unfortunate experiences; such a movement can ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
(Date:12/8/2016)... Payne, AL (PRWEB) , ... December 08, 2016 ... ... offering insurance and financial consulting services to residential and commercial clients in the ... awareness and support for Nobis Works. , Since 1977, Nobis Works has built ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... INDIANAPOLIS , Dec. 8, 2016  Eli Lilly ... detailed results of its phase 3 EXPEDITION3 trial at ... (CTAD) meeting. As previously disclosed, solanezumab did not meet ... study of solanezumab initiated in people with mild dementia ... pursue regulatory submissions for solanezumab for the treatment of ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... , Dec. 8, 2016  EIP Pharma, LLC ... obtained proof-of-mechanism for neflamapimod (previously code named VX-745), ... 2a clinical trials that demonstrated significant Alzheimer,s disease ... (12-week treatment) and Study 303 (6-week treatment) are ... in Alzheimer,s Disease (CTAD) scientific conference in ...
Breaking Medicine Technology: